Drug maker Valeant sues insurers for more than $325mn
Canadian pharmaceutical company Valeant is suing its insurers as it seeks to claw back more than $325mn in costs, as well as unspecified damages, arising from class actions following its attempted acquisition of drug firm Allergan.
Uncover exclusive insights tailored for insurance leaders
- Stay Informed: Access exclusive industry insights
- Gain a competitive advantage: Hear first about tactical developments
- Make better decisions: Understand market dynamics in crucial lines of business